227 related articles for article (PubMed ID: 32000909)
1. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.
Miller ML; Finn OJ
Methods Enzymol; 2020; 632():431-456. PubMed ID: 32000909
[TBL] [Abstract][Full Text] [Related]
2. A novel method for determining antibody-dependent cellular phagocytosis.
Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
5. The transgenic chicken derived anti-CD20 monoclonal antibodies exhibits greater anti-cancer therapeutic potential with enhanced Fc effector functions.
Kim YM; Park JS; Kim SK; Jung KM; Hwang YS; Han M; Lee HJ; Seo HW; Suh JY; Han BK; Han JY
Biomaterials; 2018 Jun; 167():58-68. PubMed ID: 29554481
[TBL] [Abstract][Full Text] [Related]
6. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
[TBL] [Abstract][Full Text] [Related]
7. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
8. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
10. Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia.
Carter MJ; Dahal LN; Cleary KLS; Marshall MJE; French RR; Beers SA; Cragg MS
Methods Mol Biol; 2019; 1881():173-184. PubMed ID: 30350206
[TBL] [Abstract][Full Text] [Related]
11. Development of a kinetic antibody-dependent cellular cytotoxicity assay.
Kamen L; Thakurta T; Myneni S; Zheng K; Chung S
J Immunol Methods; 2019 May; 468():49-54. PubMed ID: 30790564
[TBL] [Abstract][Full Text] [Related]
12. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
13. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
14. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
15. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
Front Immunol; 2021; 12():715719. PubMed ID: 34413859
[TBL] [Abstract][Full Text] [Related]
16. Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region.
González-González E; Camacho-Sandoval R; Jiménez-Uribe A; Montes-Luna A; Cortés-Paniagua I; Sánchez-Morales J; Muñoz-García L; Tenorio-Calvo AV; López-Morales CA; Velasco-Velázquez MA; Pavón L; Pérez-Tapia SM; Medina-Rivero E
J Immunol Methods; 2019 Jan; 464():87-94. PubMed ID: 30395815
[TBL] [Abstract][Full Text] [Related]
17. Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Lohse S; Loew S; Kretschmer A; Jansen JHM; Meyer S; Ten Broeke T; Rösner T; Dechant M; Derer S; Klausz K; Kellner C; Schwanbeck R; French RR; Tipton TRW; Cragg MS; Schewe DM; Peipp M; Leusen JHW; Valerius T
Br J Haematol; 2018 May; 181(3):413-417. PubMed ID: 28449349
[No Abstract] [Full Text] [Related]
18. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
19. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
20. Development of a simple new flow cytometric antibody-dependent cellular cytotoxicity (ADCC) assay with excellent sensitivity.
Tanaka M; Ishige A; Yaguchi M; Matsumoto T; Shirouzu M; Yokoyama S; Ishikawa F; Kitabayashi I; Takemori T; Harada M
J Immunol Methods; 2019 Jan; 464():74-86. PubMed ID: 30389576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]